Results 121 to 130 of about 15,823 (164)

Two Cases of Metastatic Castration-Resistant Prostate Cancer With Long-Term Survival Treated With Abiraterone. [PDF]

Clin Case Rep
Une M, Yamamoto S, Fuse H, Fujiwara R, Yonese J, Noda K.   +5 more
europepmc   +1 more source

Combined [ 223 Ra]Radiumdichloride and [ 177 Lu]Lu-PSMA-617 Therapy in End-stage Metastatic Castration-resistant Prostate Cancer. [PDF]

Clin Nucl Med
Hügle MJ, Patt M, Dierks A, Steinestel J, Lapa C.   +4 more
europepmc   +1 more source

HSP27 functional switch drives castration-resistant prostate cancer via mTOR pathway activation, highlighting promising combination therapies. [PDF]

J Exp Clin Cancer Res
Duong QH, Le TK, Tran TT, Audebert S, Camoin L, Nguyen NG, Baboudjian M, Giusiano S, Phan UTT, Zaghdoudi S, Adelaide J, Baylot V, Gleave M, Garrido C, Taïeb D, Rocchi P.   +15 more
europepmc   +1 more source

TLN1 interacts with NGFR and suppresses the development of castration-resistant prostate cancer by upregulating NGFR. [PDF]

Front Immunol
Li S, Chen A, Guo C, Gu C, Tang Z, Shen S, Yang D, Mi Y.   +7 more
europepmc   +1 more source

Cancer-control outcomes of patients with metastatic hormone-sensitive prostate cancer and ≥ 10 bone metastases receiving apalutamide: a real-world cohort. [PDF]

BMC Cancer
Wenzel M, Filzmayer M, Siech C, Le QC, Lauer B, Theissen L, Hoeh B, Heinzer H, Graefen M, Steuber T, Kriegmair M, Chun FK, Mandel P.   +12 more
europepmc   +1 more source

Metastasis of Castration-Resistant Prostate Adenocarcinoma to the Lacrimal Gland: A Case Report. [PDF]

Reports (MDPI)
Milic N, Lojanica MV, Ivanovic M, Matijasevic M, Ivanovic S.   +4 more
europepmc   +1 more source

Oligometastatic Prostate Cancer: Clues from an N-of-1. [PDF]

J Clin Med
Kirschenbaum A, Verma P, Cheung P, Yao S, Drummond C, Tipi I, Yao A, Levine AC.   +7 more
europepmc   +1 more source

Comparative Digital Estrogen Receptor Alpha (ERα) Expression Analysis in Benign and Malignant Prostate Tissue of Men and Dogs. [PDF]

Prostate
Lothion-Roy J, Aeschlimann L, Hiller LA, Rottenberg S, Mongan NP, Rutland CS, Rakha E, Dean A, Rubin MA, de Brot S.   +9 more
europepmc   +1 more source

USP13 promotes enzalutamide resistance by catalyzing depolyubiquitination of PCMT1 in prostate cancer. [PDF]

Cell Death Dis
Wang Z, Liu X, Li Z, Yuan R, Zheng F, Xiong S, Zeng J, Pang W, Fu B, Li S, Xu S, Deng J.   +11 more
europepmc   +1 more source

Evaluating synergistic versus additive effects of the triplet regimen in metastatic castration-sensitive prostate cancer: a modeling analysis. [PDF]

Jpn J Clin Oncol
Hata S, Suzuki S, Fujinami H, Yamanaka N, Shin T.   +4 more
europepmc   +1 more source